Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.54 |
| ▸ | SCD5 | Q86SK9 | 10/20 | 0.52 |
| ▸ | SCD | O00767 | 9/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412244 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2SCD5SCD | |
| SCHEMBL2896726 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2SCD5SCD | |
| SCHEMBL13412243 | 0.88 | GRM5 (0.46) | HCRTR1HCRTR2SCD5 | |
| SCHEMBL5478785 | 0.88 | SMN1; SMN2 (0.48) | HCRTR1HCRTR2NPC1RAB9A | |
| SCHEMBL2890825 | 0.88 | GRM5 (0.46) | HCRTR1HCRTR2SCD5 | |
| SCHEMBL8226950 | 0.88 | HCRTR1 (0.44) | HCRTR1HCRTR2SCD5SCDNPC1 | |
| SCHEMBL4344394 | 0.86 | SCD5 (0.56) | HCRTR1HCRTR2SCD5SCD | |
| SCHEMBL2899238 | 0.86 | SCD5 (0.56) | HCRTR1HCRTR2SCD5SCD | |
| SCHEMBL8229293 | 0.85 | NPC1 (0.42) | HCRTR1HCRTR2SCD5SCDNPC1 | |
| SCHEMBL2889901 | 0.85 | SMN1; SMN2 (0.48) | HCRTR1HCRTR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111823-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| WO-2009054792-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| US-20090111823-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111823-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111823-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009054792-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111823-A1 | AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM2 | HCRTR1 834/4885HCRTR2 370/4885SCD5 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.